Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision

 

 

ZURICH, Switzerland and FREMONT, Calif.,Radarseluma.Disway.Id,-- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.

 

--

This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.

This integrated approach enhances our understanding of biomarkers by combining deep unbiased DIA-MS discovery proteomics with highly specific and ultra-sensitive mid- and high-plex NULISA assays for low-abundance proteins such as cytokines, chemokines and important disease protein biomarkers from plasma.

 

BACA JUGA:Pengusutan Dana Stunting Ditangani Jaksa, Polres Seluma Hentikan Penyelidikan

In the Industry Spotlight Theater session hosted by Alamar at the American Society for Cancer Research (AACR) 2024 Annual Meeting in San Diego on April 9 at 12:30 pm PT, the companies will jointly present data from a collaborative study focused on Non-Small Cell Lung Cancer (NSCLC).

 

In this study, plasma samples from a cohort of NSCLC patients were analyzed using both the Biognosys TrueDiscovery® unbiased discovery platform and Alamar’s NULISAseq™ Inflammation Panel 250. The findings demonstrate the feasibility of integrated analysis and highlight the complementary insights derived from mass spectrometry and affinity-based assays in plasma.

 

Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.

Sumber: